BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 556 filers reported holding BIO-TECHNE CORP in Q3 2021. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,080,612 | +21.9% | 15,875 | +46.2% | 0.15% | +28.1% |
| Q2 2023 | $886,502 | +10.0% | 10,860 | 0.0% | 0.11% | +4.6% |
| Q1 2023 | $805,704 | -10.5% | 10,860 | 0.0% | 0.11% | -13.5% |
| Q4 2022 | $900,077 | +16.7% | 10,860 | +300.0% | 0.13% | +7.7% |
| Q3 2022 | $771,000 | -18.1% | 2,715 | 0.0% | 0.12% | -14.0% |
| Q2 2022 | $941,000 | -20.0% | 2,715 | 0.0% | 0.14% | -7.5% |
| Q1 2022 | $1,176,000 | -28.2% | 2,715 | -14.2% | 0.15% | -21.4% |
| Q4 2021 | $1,637,000 | +6.7% | 3,165 | 0.0% | 0.19% | -4.1% |
| Q3 2021 | $1,534,000 | -1.7% | 3,165 | -8.7% | 0.20% | -1.0% |
| Q2 2021 | $1,560,000 | +65.8% | 3,465 | +40.6% | 0.20% | +45.9% |
| Q1 2021 | $941,000 | -27.1% | 2,465 | -39.4% | 0.14% | -9.4% |
| Q4 2020 | $1,291,000 | +20.0% | 4,065 | -6.4% | 0.15% | +8.0% |
| Q3 2020 | $1,076,000 | -6.2% | 4,345 | 0.0% | 0.14% | -15.3% |
| Q2 2020 | $1,147,000 | +39.2% | 4,345 | 0.0% | 0.16% | +8.7% |
| Q1 2020 | $824,000 | -13.6% | 4,345 | 0.0% | 0.15% | +9.5% |
| Q4 2019 | $954,000 | -1.4% | 4,345 | -12.1% | 0.14% | -9.9% |
| Q3 2019 | $968,000 | -6.1% | 4,945 | 0.0% | 0.15% | -6.2% |
| Q2 2019 | $1,031,000 | +5.0% | 4,945 | 0.0% | 0.16% | -8.5% |
| Q1 2019 | $982,000 | +31.8% | 4,945 | -3.9% | 0.18% | +13.5% |
| Q4 2018 | $745,000 | -29.0% | 5,145 | 0.0% | 0.16% | -16.6% |
| Q3 2018 | $1,050,000 | +3.7% | 5,145 | -24.8% | 0.19% | -2.1% |
| Q2 2018 | $1,013,000 | -2.0% | 6,845 | 0.0% | 0.19% | -3.5% |
| Q1 2018 | $1,034,000 | +16.6% | 6,845 | 0.0% | 0.20% | +13.1% |
| Q4 2017 | $887,000 | +4.1% | 6,845 | -2.8% | 0.18% | -4.9% |
| Q3 2017 | $852,000 | +4.4% | 7,045 | +1.4% | 0.18% | +4.5% |
| Q2 2017 | $816,000 | +15.6% | 6,945 | 0.0% | 0.18% | +9.3% |
| Q1 2017 | $706,000 | -1.1% | 6,945 | 0.0% | 0.16% | -1.8% |
| Q4 2016 | $714,000 | -6.1% | 6,945 | 0.0% | 0.16% | -6.8% |
| Q3 2016 | $760,000 | -2.9% | 6,945 | 0.0% | 0.18% | -4.9% |
| Q2 2016 | $783,000 | +19.4% | 6,945 | 0.0% | 0.18% | +18.6% |
| Q1 2016 | $656,000 | +5.0% | 6,945 | 0.0% | 0.16% | +2.0% |
| Q4 2015 | $625,000 | -2.6% | 6,945 | 0.0% | 0.15% | -3.8% |
| Q3 2015 | $642,000 | +16.5% | 6,945 | +24.0% | 0.16% | +27.2% |
| Q2 2015 | $551,000 | -16.8% | 5,600 | -15.2% | 0.12% | -13.8% |
| Q1 2015 | $662,000 | +0.9% | 6,600 | -7.0% | 0.14% | +1.4% |
| Q4 2014 | $656,000 | – | 7,100 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |